Glioblastoma (GBM) is the most aggressive primary brain tumor. Molecular classification — IDH status, EGFR amplification, MGMT methylation — guides prognosis and emerging therapeutic strategies. abinScience provides validated antibodies, recombinant proteins, and biosimilar-grade reference proteins for the targets listed below. RUO
EGFR / EGFRvIII
ErbB1
EGFR amplified in ~60% of primary GBM; EGFRvIII is a tumor-specific neoantigen. 108 products. Validated: Blocking, ELISA, FC, IHC, SPR, WB.
Antibodies • Biosimilars • Proteins
IDH1 / IDH2
Isocitrate Dehydrogenase
IDH1 R132H defines lower-grade gliomas. Now therapeutic target (vorasidenib). 7 products. Validated: ELISA, IHC, WB.
Antibodies • Proteins
GFAP
Glial Fibrillary Acidic Protein
Canonical astrocyte/glial tumor marker. Serum biomarker for brain injury. 13 products. Validated: ELISA, IF, IHC, WB.
Antibodies • Proteins
PDGFRα/β
Platelet-Derived Growth Factor Receptor
PDGFRA amplification defines proneural GBM subtype. 46 products. Validated: ELISA, FC, IHC, WB.
Antibodies • Biosimilars • Proteins
VEGF
Angiogenesis
GBM is highly vascular; bevacizumab targets VEGF-A. 122 products. Validated: Blocking, ELISA, FC, IHC, SPR, WB.
Antibodies • Biosimilars • Proteins
PD-L1
CD274
Checkpoint target for GBM immunotherapy research. 130 products. Validated: Blocking, ELISA, FC, IF, IHC, WB.
Antibodies • Biosimilars • Proteins
Olig2
Oligodendrocyte TF
Glioma lineage marker for tumor classification. 3 products. Validated: ELISA, IHC, WB.
Antibodies • Proteins
TERT
Telomerase Reverse Transcriptase
TERT promoter mutation is a GBM diagnostic criterion. 10 products. Validated: ELISA.
Antibodies • Proteins
IHC-Validated AntibodiesAntibodies with IHC validation available for: EGFR, IDH1, GFAP, PDGFR, VEGF, PD-L1. See individual product pages for clone details and recommended dilutions.
Flow Cytometry ReadyFC-validated antibodies available for: EGFR, PDGFR, VEGF, PD-L1. Multiple conjugates (FITC, APC, PE, PerCP) offered for select clones.
Research-Grade BiosimilarsBiosimilar-grade reference proteins with ELISA and FACS validation for: EGFR, PDGFR, VEGF, PD-L1.
Original Manufacturer PricingDirect-from-manufacturer pricing with no distributor markup. Bulk and custom conjugation options available.
What PD-L1 reagents do you offer?
We offer 58 detection antibodies, 59 research-grade biosimilar proteins, and 13 recombinant proteins. Validated applications include: Blocking, ELISA, FC, IF, IHC, WB. Available clones include: 22C3 (ELISA, FC, IHC, WB; APC, FITC, PE), Polyclonal (ELISA, IHC, WB; unconjugated), SP142 (ELISA, IHC, WB; unconjugated). Research-grade biosimilar proteins also available (e.g., Envafolimab, Pacmilimab, Cosibelimab).
What VEGF reagents do you offer?
We offer 66 detection antibodies, 39 research-grade biosimilar proteins, and 17 recombinant proteins. Validated applications include: Blocking, ELISA, FC, IHC, SPR, WB. Available clones include: Polyclonal (ELISA, IHC, WB; unconjugated), 1A169 (ELISA, IHC, WB; unconjugated), YW64.3 (ELISA, FC; APC, FITC, PE). Research-grade biosimilar proteins also available (e.g., Vesencumab, Navicixizumab, Dilpacimab).
What EGFR / EGFRvIII reagents do you offer?
We offer 45 detection antibodies, 49 research-grade biosimilar proteins, and 14 recombinant proteins. Validated applications include: Blocking, ELISA, FC, IHC, SPR, WB. Available clones include: SAA2220 (ELISA, FC, IHC, WB; APC, FITC, PE), Polyclonal (ELISA, IHC, WB; unconjugated), 11F8 (ELISA, FC, WB; APC, FITC, PE). Research-grade biosimilar proteins also available (e.g., Modotuximab, Tomuzotuximab, Depatuxizumab).
What PDGFRα/β reagents do you offer?
We offer 28 detection antibodies, 5 research-grade biosimilar proteins, and 13 recombinant proteins. Validated applications include: ELISA, FC, IHC, WB. Available clones include: Polyclonal (ELISA, IHC, WB; unconjugated), SAA0056 (FC; APC, FITC, PE), SAA0057 (FC; APC, FITC, PE). Research-grade biosimilar proteins also available (e.g., Tovetumab, Rinucumab, Olaratumab).
Can I get custom antibodies for novel targets?
Yes — our parent company AtaGenix provides full custom antibody development from immunogen design through hybridoma production and characterization, including targets not yet in our catalog.
中文
English
한국어
日本語
Español
Français
Русский
